Trials / Conditions / Treatment Resistant Depression

Treatment Resistant Depression

253 registered clinical trials studyying Treatment Resistant Depression — 68 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder NCT07499583	Indiana University	Phase 1 / Phase 2
Not Yet Recruiting	Early Brainwave Biomarkers for Personalized Neuromodulation in Treatment-resistant Depression NCT07528157	Stanford University	N/A
Not Yet Recruiting	InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression NCT06781697	Sunnybrook Health Sciences Centre	Phase 3
Not Yet Recruiting	Mindfulness Engaged Neurostimulation for Depression (MEND II) NCT07512284	University of California, San Diego	Phase 2
Not Yet Recruiting	Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression NCT07211438	Centre for Addiction and Mental Health	Phase 2
Not Yet Recruiting	ipRGC as a Potential Biomarker for Predicting Transcranial Magnetic Stimulation Treatment Response in Major De NCT07474974	Polytechnic Institute of Porto	N/A
Not Yet Recruiting	A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcra NCT07227103	NeuroRx, Inc.	Phase 2 / Phase 3
Withdrawn	N2O for Acute Suicidality and Depression in the ED NCT05710887	University of Chicago	Phase 2
Not Yet Recruiting	Sustained Mood Improvement With Laughing Gas Exposure NCT07262008	Women's College Hospital	Phase 3
Enrolling By Invitation	Stereotactic Radiotherapy Treatment for Treatment-resistant Depression NCT07274917	Capital Medical University	N/A
Not Yet Recruiting	Vagus Nerve Stimulation (VNS) Electroencephalogram (EEG) Protocol Supplement NCT07310381	Stanford University	N/A
Not Yet Recruiting	Randomized Controlled Trial Testing the Efficacy of Transcranial Magnetic Stimulation by Accelerated & High-do NCT07188753	Rennes University Hospital	N/A
Recruiting	Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression NCT07183748	Beersheva Mental Health Center	Phase 2
Not Yet Recruiting	Mental Health Mission Mood Disorder Cohort Study NCT07189689	University of Oxford	—
Recruiting	Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression NCT07166289	Laureate Institute for Brain Research, Inc.	N/A
Recruiting	Characterizing Dopamine Receptor Binding in Treatment Resistant Depression NCT03537794	Unity Health Toronto	—
Recruiting	Focused Ultrasound Neuromodulation in Patients With Treatment-Resistant Depression NCT07094789	Sunnybrook Health Sciences Centre	N/A
Recruiting	Ketamine Augmentation of ECT in Treatment-Resistant Depression NCT07088380	Università Vita-Salute San Raffaele	Phase 3
Recruiting	Magnetic Resonance-Guided Focused Ultrasound Bilateral Capsulotomy for the Treatment of Refractory Bipolar Dep NCT07108257	Sunnybrook Health Sciences Centre	N/A
Not Yet Recruiting	Neurocardiac Predictors of Treatment Response to RTMS in Depression NCT05139862	University of British Columbia	N/A
Recruiting	Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression NCT06512220	Centre for Addiction and Mental Health	Phase 2
Completed	Multiple Ascending Dose Phase 1 Study of ALA-3000 NCT06965569	Alar Pharmaceuticals Inc.	Phase 1
Recruiting	Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND) NCT06518720	Centre for Addiction and Mental Health	Phase 2
Recruiting	Maintenance rTMS for Depression (Maitr-De) NCT06938841	University of California, San Diego	N/A
Active Not Recruiting	Transcranial Direct Current Stimulation (tDCS) as an Adjunctive Treatment for Treatment Resistant Depression ( NCT06236711	Mayo Clinic	N/A
Active Not Recruiting	Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression NCT05774665	Massachusetts General Hospital	Phase 2
Recruiting	COpenhagen Magnetic Personalized Accelerated Brain Circuit Therapy for Treatment Resistant Depression NCT06895863	Danish Research Centre for Magnetic Resonance	N/A
Recruiting	Psilocybin rTMS for Treatment Resistant Depression NCT06132178	University of Texas at Austin	Phase 2
Recruiting	The Impact of Working Memory and Reward Markers on DLPFC Activity in Treatment-resistant Depression NCT06163625	Unity Health Toronto	N/A
Recruiting	A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients NCT06524830	atai Therapeutics, Inc.	Phase 2
Completed	A Multiple Case Study of Schema Therapy for Difficult-to-treat Depression- DEPRE-ST*Case NCT06655623	Region of Southern Denmark	N/A
Not Yet Recruiting	Studying Patterns in Patient Engagement Among Treatment Resistant Depression Patients NCT06101914	Power Life Sciences Inc.	—
Recruiting	Psilocybin for Treatment-Resistant Depression in Autism NCT06731621	Centre for Addiction and Mental Health	Phase 1
Completed	Dose-Optimized and Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression NCT06730841	University of California, San Diego	N/A
Recruiting	Physical Activity Program for TRD NCT06404320	Unity Health Toronto	N/A
Recruiting	Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND) NCT06423430	Abbott Medical Devices	N/A
Recruiting	Natural History of Depression, Bipolar Disorder and Suicide Risk NCT06462196	National Institute of Mental Health (NIMH)	—
Recruiting	The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treat NCT05973851	Dr. Inge Winter	Phase 3
Not Yet Recruiting	Efficacy of Deep Brain Stimulation(DBS) for Treatment-Resistant Depression(TRD) NCT06542900	Xuanwu Hospital, Beijing	N/A
Recruiting	Identifying Local Field Potential Biomarkers for Treatment-Resistant Major Depression With Deep Brain Stimulat NCT06542094	West China Hospital	N/A
Terminated	Combining rTMS and tDCS in Depression: an Exploratory Clinical Trial NCT06500533	Regionspsykiatrien Gødstrup	N/A
Active Not Recruiting	Psilocybin for Treatment-Resistant Depression NCT06230757	University of Colorado, Denver	Phase 2
Recruiting	Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression NCT06278779	The George Institute	Phase 4
Withdrawn	SAINT for Treatment of Preoperative Depression to Reduce Opioid Use Following Arthroplasty NCT04195308	Stanford University	N/A
Recruiting	Psilocybin for Hospitalized Patients with Treatment-resistant Depression NCT06378229	University Hospital, Ghent	Phase 2
Active Not Recruiting	Mindfulness Engaged Neurostimulation for Depression NCT06399406	University of California, San Diego	Phase 2
Recruiting	Belief Updating in Treatment Resistant Depression NCT05577247	Assistance Publique - Hôpitaux de Paris	—
Withdrawn	First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM) NCT05921929	ReST Therapeutics	Phase 1
Recruiting	Psilocybin-Assisted Therapy in Treatment-Resistant Depression NCT06303739	University of North Carolina, Chapel Hill	Phase 3
Recruiting	pBFS-guided rTMS Over DMPFC for Treatment-Resistant Depression NCT06350396	Changping Laboratory	N/A
Active Not Recruiting	Studying the Health of Asians to Advance Knowledge, Treatments, and Interventions for Depression NCT06002204	University of Texas Southwestern Medical Center	—
Completed	Ketogenic Diet for Treatment-Resistant Depression: Dietary Interventions for MEntal Health Study (DIME) NCT06091163	University of Oxford	N/A
Unknown	pBFS Guided rTMS Over Different Targets for Treatment-Resistant Depression NCT06255561	Changping Laboratory	N/A
Suspended	Low-Intensity Focused Ultrasound for Treatment-Resistant Depression NCT06013384	Medical University of South Carolina	N/A
Recruiting	Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psiloc NCT06341426	University Health Network, Toronto	Phase 2
Unknown	Transcranial Alternating Current Stimulation for Treatment-Resistant Depression NCT06172413	Xuanwu Hospital, Beijing	N/A
Active Not Recruiting	Exercise to Augment TMS in Those With Treatment Resistant Depression NCT05913401	Butler Hospital	N/A
Recruiting	Olfactory and Brain Stimulations in Treatment-resistant Depression NCT05661383	Hôpital le Vinatier	N/A
Unknown	Predictors of Intravenous Ketamine Response in TRD NCT05625555	Abraham Nunes	Phase 3
Unknown	Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis NCT06329414	University of Utah	—
Recruiting	i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Cl NCT06480500	University Health Network, Toronto	Phase 2
Suspended	Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression NCT06480201	Texas A&M University	Phase 1
Unknown	Stanford Neuromodulation Therapy (SNT) for the Treatment-Resistant Depression NCT06166082	Changping Laboratory	N/A
Active Not Recruiting	Open Label - Personalized Therapeutic Neuromodulation for Anhedonic Depression NCT06052137	Stanford University	N/A
Recruiting	Dutch-Depression Outcome Trial Comparing 5 Day Multi Daily Neuronavigated Theta Burst Sessions With 6 Weeks rT NCT05900271	Amsterdam UMC, location VUmc	N/A
Unknown	rTMS Therapy for Treatment-Resistant Depression With Different Targets Guided by pBFS NCT06095778	Changping Laboratory	N/A
Enrolling By Invitation	Positron Emission Tomography in Transcranial Magnetic Stimulation Intervention for Treatment-resistant Depress NCT06044324	First Affiliated Hospital of Zhejiang University	N/A
Recruiting	DBS for Depression NCT06096207	Northwell Health	Phase 1
Recruiting	40 Hz Light Neurostimulation for Patients With Depression (FELIX) NCT05680220	Klaus Martiny	N/A
Completed	KET-RO Plus RO DBT for Treatment Resistant Depression NCT06138691	Washington University School of Medicine	Phase 1
Completed	BPL-003 Efficacy and Safety in Treatment Resistant Depression NCT05870540	Beckley Psytech Limited	Phase 2
Unknown	pBFS-Guided rTMS Therapy Over Different Targets for Treatment-Resistant Depression NCT05976009	Changping Laboratory	N/A
Unknown	pBFS Guided rTMS Therapy Over Different Targets for Treatment-Resistant Depression NCT05976022	Changping Laboratory	N/A
Unknown	pBFS Guided rTMS Over DMPFC for Treatment-Resistant Depression NCT05948839	Changping Laboratory	N/A
Active Not Recruiting	Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders NCT05838560	Washington University School of Medicine	Phase 2
Recruiting	Does Psilocybin Require Psychedelic Effects to Treat Depression? NCT05710237	Centre for Addiction and Mental Health	Phase 2
Unknown	pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression NCT05842291	Changping Laboratory	N/A
Completed	A Trial of GH001 in Patients With Treatment-resistant Depression NCT05800860	GH Research Ireland Limited	Phase 2
Unknown	Accelerated High-dose Sequential Bilateral Theta Burst Stimulation for Treatment Resistant Depression NCT05811104	University of Calgary	N/A
Unknown	Transcranial Ultrasonic Stimulation in Treatment-resistant Depression : an Open-label Pilot Trial NCT06085950	Centre Hospitalier St Anne	N/A
Completed	Observation of Safety and Tolerability Within 1 Year of the Use of R-ketamine / Placebo in Drug-resistant Depr NCT06232291	Medical University of Gdansk	—
Recruiting	Schema Therapy for Patients With Chronic Treatment Resistant Depression NCT05833087	Region of Southern Denmark	N/A
Completed	Adjuvant Accelerated piTBS for Reducing Suicidal Ideation in TRD Patients NCT06372834	Tri-Service General Hospital	N/A
Recruiting	IV Ketamine vs. IN Esketamine for MDD TRD NCT06488586	Gustavo Vazquez	—
Completed	Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resista NCT05454410	Novartis Pharmaceuticals	Phase 2
Recruiting	Disruptions of Brain Networks and Sleep by Electroconvulsive Therapy NCT05905705	Washington University School of Medicine	—
Recruiting	DBS for TRD With the Medtronic Percept PC NCT05773755	Helen Mayberg, MD	N/A
Recruiting	Translational Biomarkers in Accelerated Neuromodulation for Treatment-resistant Depression NCT05798143	ITAB - Institute for Advanced Biomedical Technologies	N/A
Active Not Recruiting	Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD NCT05711940	COMPASS Pathways	Phase 3
Recruiting	An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Trea NCT05660642	Beckley Psytech Limited	Phase 2
Active Not Recruiting	Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD NCT05624268	COMPASS Pathways	Phase 3
Recruiting	The Mechanisms of Underlying Accelerated Repetitive Transcranial Magnetic Stimulation for Treatment-resistant NCT05607654	First Affiliated Hospital of Zhejiang University	N/A
Unknown	Early Identification of TRD and Construction and Clinical Validation of NTBS Precision Technology NCT05777876	First Affiliated Hospital of Zhejiang University	N/A
Recruiting	Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disor NCT05849402	Stanford University	N/A
Completed	Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression NCT05615948	Maimonides Medical Center	Phase 4
Recruiting	Tractography Guided Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression NCT03952962	Nader Pouratian	N/A
Recruiting	Cortical Inhibition as a Biomarker of Response in a Comparison of Bilateral Versus Unilateral Accelerated Thet NCT05377177	University of California, San Diego	N/A
Recruiting	Home-based Transcranial Direct Current Stimulation for Treatment Resistant Depression NCT05595356	Hospital de Clinicas de Porto Alegre	N/A
Recruiting	Glutamate Emotion Memory Study NCT05809609	University of Oxford	N/A
Completed	A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TR NCT05113771	Denovo Biopharma LLC	Phase 2
Unknown	Dorsomedial Prefrontal Neuromodulation in Treatment-resistant Depression NCT05422417	Taipei Veterans General Hospital, Taiwan	N/A
Suspended	Enhanced Spatial Targeting in ECT Utilizing FEAST NCT04099342	University of Minnesota	N/A
Completed	Personalized Therapeutic Neuromodulation for Anhedonic Depression NCT05144789	Stanford University	N/A
Recruiting	Mapping and Modulating the Spatiotemporal Dynamics of Socio-Affective Processing NCT05418894	Baylor College of Medicine	N/A
Unknown	An Intervention Study of Anhedonia and Pain Empathy in Depression NCT05355142	Anhui Medical University	N/A
Completed	The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ide NCT05220410	Sheppard Pratt Health System	Phase 2
Completed	Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression NCT05045378	Taipei Veterans General Hospital, Taiwan	Phase 4
Completed	Intensive TMS for Bipolar Depression NCT05228457	University of Pennsylvania	N/A
Unknown	Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Tolerability of Treatment Durations Rangi NCT03986658	NeuroQore Inc.	N/A
Completed	A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD NCT05414422	Perception Neuroscience	Phase 2
Completed	Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression NCT05066672	Navitor Pharmaceuticals, Inc.	Phase 2
Completed	Accelerated Intermittent Theta Burst Stimulation for Depressed Patients During the Covid-19 Pandemic NCT04935489	Ontario Shores Centre for Mental Health Sciences	N/A
Recruiting	A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients NCT04996433	University of Greifswald	N/A
Completed	Psilocybin for Treatment-Resistant Depression NCT05029466	Brain and Cognition Discovery Foundation	Phase 2
Terminated	Effect of Ketamine on Neurological Activity as Measured by Electroencephalogram (EEG) NCT05095792	Entheon Biomedical Corp.	—
Completed	Sustained Mood Improvement With Laughing Gas Exposure: A Randomized Controlled Pilot Trial NCT04957368	Unity Health Toronto	Phase 4
Unknown	Accelerated TBS in Late Life Depression NCT05119699	Centre for Addiction and Mental Health	N/A
Recruiting	PCS in Severe Treatment Resistant Depression NCT04124341	University of Minnesota	N/A
Completed	Stellate Ganglion Block for Major Depressive Disorder. NCT04727229	Unity Health Toronto	Phase 4
Recruiting	Biomarker-guided rTMS for Treatment Resistant Depression NCT04041479	Weill Medical College of Cornell University	Phase 3
Withdrawn	Investigational TMS Treatment for Depression NCT03175887	White River Junction Veterans Affairs Medical Center	N/A
Unknown	Reward Emotion Learning and Ketamine Study NCT04850911	University of Oxford	N/A
Unknown	Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant NCT04936126	All India Institute of Medical Sciences, Bhubaneswar	Phase 4
Withdrawn	ECT vs. Esketamine NCT04924257	Medical University Innsbruck	Phase 3
Completed	Development of Neuro-Navigated Transcranial Magnetic Stimulation (TMS) Using MRI NCT05598931	Soterix Medical	—
Withdrawn	Cannabidiol for Treatment Resistant Depression NCT04732169	University of Alabama at Birmingham	Phase 4
Completed	Virtual Neuro-Navigation System for Personalized Community Based TMS NCT04956081	Soterix Medical	N/A
Recruiting	Antidepressant Effects of Nitrous Oxide NCT05357040	University of Chicago	Phase 2
Active Not Recruiting	Rapid Acting Transcranial Magnetic Stimulation NCT04739969	Stanford University	N/A
Completed	Establishing a Dose-response Relationship With Accelerated Transcranial Magnetic Stimulation NCT04243798	Stanford University	N/A
Terminated	Antidepressant Effects of TS-161 in Treatment-Resistant Depression NCT04821271	National Institute of Mental Health (NIMH)	Phase 2
Completed	Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression NCT04670081	Central Institute of Mental Health, Mannheim	Phase 2
Terminated	Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resi NCT04663321	Merck Sharp & Dohme LLC	Phase 2
Unknown	Psilocybin Versus Ketamine in Treatment-Resistant Depression NCT05383313	National Institute of Mental Health, Czech Republic	Phase 2
Completed	MAO-B Occupancy in Depressed Patients NCT04841798	Centre for Addiction and Mental Health	N/A
Unknown	An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients NCT04971291	Axsome Therapeutics, Inc.	Phase 2
Terminated	The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Asse NCT04753385	LivaNova	—
Unknown	The Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Major Depressive Disorder NCT04805879	University of Calgary	Phase 2 / Phase 3
Unknown	The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. NCT04433845	Sheppard Pratt Health System	Phase 2
Active Not Recruiting	An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depressi NCT04433858	Sheppard Pratt Health System	Phase 2
Completed	Home-administered tDCS for Treatment of Depression NCT04781127	Soterix Medical	Phase 1
Completed	Pharmacogenetics Associated With IV Ketamine NCT04695405	Brain and Cognition Discovery Foundation	—
Active Not Recruiting	Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I NCT04680910	Washington University School of Medicine	Phase 1
Completed	Deciphering Principles of Network Dynamics Underlying Depression Symptom Severity From Multi-day Intracranial NCT06953362	University of California, San Francisco	—
Recruiting	University of Iowa Interventional Psychiatry Service Patient Registry NCT04480918	Mark Niciu	—
Completed	Ketamine for Older Adults Pilot NCT04504175	Washington University School of Medicine	Phase 4
Terminated	Tianeptine for Treatment Resistant Depression NCT04249596	Jonathan A. Javitch, MD, PhD	Phase 4
Active Not Recruiting	CET- REM (Correlating ECT Response to EEG Markers) NCT04451135	Washington University School of Medicine	N/A
Terminated	Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE) NCT04634669	Axsome Therapeutics, Inc.	Phase 2
Unknown	Psilocybin in Depression Resistant to Standard Treatments NCT04959253	King's College London	Phase 2
Completed	Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality NCT04101474	Assiut University	N/A
Completed	Mechanistic Evaluation of Response in TRD (MERIT) NCT04608396	Axsome Therapeutics, Inc.	Phase 2
Completed	The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depres NCT04739865	COMPASS Pathways	Phase 2
Completed	Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU) NCT04519957	COMPASS Pathways	—
Completed	Investigation of the Effects of Repetitive Transcranial Magnetic Stimulation on Cognition in Depression NCT03977038	Sunnybrook Health Sciences Centre	—
Completed	Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder NCT04226352	Johns Hopkins University	Phase 1
Completed	Computational Psychiatric Approach to Depression NCT04189939	Wake Forest University Health Sciences	—
Completed	Brain Reactivity to Nitrous Oxyde in Depression : an MRI and Ultrasound Study (PROTOBRAIN Pilote) NCT04199143	University Hospital, Tours	N/A
Active Not Recruiting	Compressed Intermittent Theta Burst Stimulation NCT04684706	University of Pennsylvania	N/A
Completed	Minocycline as Adjunctive Treatment for Treatment Resistant Depression NCT03947827	Centre for Addiction and Mental Health	Phase 3
Active Not Recruiting	DBS for TRD With the Medtronic Summit RC+S NCT04106466	Helen Mayberg, MD	N/A
Completed	A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders NCT04226963	Medical University of Gdansk	—
Unknown	Efficacy of Deep Anaesthesia With Isoflurane as a Fast-response Antidepressant Agent NCT04171193	University of Sao Paulo	Phase 2
Completed	Clinical Study of GH001 in Depression NCT04698603	GH Research Ireland Limited	Phase 1 / Phase 2
Recruiting	A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of NCT03887715	LivaNova	N/A
Unknown	Neurobiological Analyses Within the FORESEE III Study NCT04021823	University Hospital Freiburg	—
Completed	RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT) NCT05531591	Centre for Addiction and Mental Health	Phase 4
Unknown	Brain-derived Neurotrophic Factor and the Antidepressant Efficacy of Brain Stimulation NCT04076124	Taipei Veterans General Hospital, Taiwan	N/A
Completed	Dorsomedial Prefrontal Cortex and the Antidepressant Efficacy of Theta Burst Stimulation in Depressed Patients NCT04037592	Taipei Veterans General Hospital, Taiwan	N/A
Completed	Open-Label Safety Study of AXS-05 in Subjects With Depression NCT04039022	Axsome Therapeutics, Inc.	Phase 3
Completed	Pilot Accelerated Theta Burst in Treatment-Resistant Bipolar Depression NCT03953417	Stanford University	N/A
Unknown	Antidepressant Discontinuation in Treatment Resistant Depression NCT03786614	University of Louisville	N/A
Unknown	Deep Brain Stimulation for Treatment Resistant Depression NCT04009928	Sunnybrook Health Sciences Centre	Phase 1 / Phase 2
Withdrawn	Glabellar Botulinum Toxin Injections for the Treatment of Geriatric Depression NCT03833063	Helse Stavanger HF	Phase 1
Active Not Recruiting	Neural and Antidepressant Effects of Propofol NCT03684447	University of Utah	Phase 2 / Phase 3
Withdrawn	Neural and Antidepressant Effects of Propofol (Phase 2) NCT03923361	University of Utah	Phase 2 / Phase 3
Completed	Nitrous Oxide for Major Depressive Disorder NCT03932825	Lingjiang Li	Phase 2
Completed	The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression NCT03775200	COMPASS Pathways	Phase 2
Completed	Psychotherapeutic Augmentation of Brain Stimulation Effects NCT04159285	Charite University, Berlin, Germany	N/A
Active Not Recruiting	Ketamine Associated ACC GABA and Glutamate Change and Depression Remission: NCT03573349	Mayo Clinic	EARLY_Phase 1
Completed	Simvastatin as an Augmentation Treatment for Treatment Resistant Depression: Randomized Controlled Trial. NCT03435744	Pakistan Institute of Living and Learning	Phase 3
Terminated	Salicylic Augmentation in Depression NCT03152409	Jessica Harder	Phase 2
Unknown	Cost-utility Analysis of Maintenance rTMS for Treatment-resistant Depression NCT03701724	Nantes University Hospital	N/A
Completed	Efficacy of Convulsive Therapies During Continuation NCT03711019	Centre for Addiction and Mental Health	N/A
Completed	Neurofeedback for Treatment Resistant Depression NCT03428828	Kymberly Young	N/A
Unknown	Evaluation of Schemes of Administration of Intravenous Ketamine in Depression NCT03742557	National Institute of Neurology and Neurosurgery, Mexico	Phase 3
Unknown	Efficacy Study of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression NCT03653858	University Hospital Freiburg	N/A
Completed	Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine NCT04856124	Psych Atlanta	—
Terminated	SSM vs HEP in Late-Life Depression NCT03564041	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	N/A
Completed	Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression NCT03191058	University of Texas Southwestern Medical Center	N/A
Completed	Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treat NCT03606395	Navitor Pharmaceuticals, Inc.	Phase 1
Withdrawn	Deep Brain Stimulation to Relieve Depression NCT02889250	Jordan F. Karp	Phase 3
Completed	PF-04995274 and Emotional Processing in Treatment Resistant Depression NCT03515733	University of Oxford	Phase 1
Completed	Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study NCT03680781	Stanford University	N/A
Withdrawn	Efficacy and Safety of TAK-653 in Treatment-Resistant Depression NCT03312894	Millennium Pharmaceuticals, Inc.	Phase 2
Completed	Psychosocial Characteristics and Non-pharmacological Intervention of Patients With Treatment-resistant Depress NCT03329391	National Taiwan University Hospital	N/A
Unknown	rTMS Intervention on Motivational Anhedonia of Treatment Resistant Depression and Brian Network Mechanism NCT03991572	Anhui Medical University	N/A
Recruiting	A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression. NCT03320304	LivaNova	—
Withdrawn	Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine NCT03290963	William V. Bobo, M.D.	Phase 2
Terminated	Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression NCT02675556	Joshua M Hare	Phase 1
Completed	Stepped Care AiTBS 2 Depression Study (Ghent) NCT03288675	University Hospital, Ghent	N/A
Recruiting	ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression NCT03272698	University of Saskatchewan	Phase 4
Unknown	TBS in Major Depression NCT03257397	Rupert Lanzenberger	N/A
Completed	Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression: OL Cohort NCT03240692	Stanford University	N/A
Completed	Neuroimaging in Patients Undergoing TMS for Depression NCT02974296	New York State Psychiatric Institute	N/A
Completed	ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) NCT03113968	Bo Hu	Phase 2 / Phase 3
Completed	Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD) NCT03068715	Stanford University	N/A
Completed	Optimizing Outcomes of Treatment-Resistant Depression in Older Adults NCT02960763	Washington University School of Medicine	Phase 4
Unknown	PINS Stimulator System for Patients With Treatment Resistant Depression NCT02253355	Beijing Pins Medical Co., Ltd	EARLY_Phase 1
Unknown	Effects of TBS on 5-HT1A Receptor Binding NCT02810717	Rupert Lanzenberger	N/A
Terminated	The UTHealth Ketamine Project NCT02882711	The University of Texas Health Science Center, Houston	Phase 2
Completed	Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients NCT02935595	The University of Texas Health Science Center, Houston	Phase 2
Completed	Neurocognitive Features of Patients With Treatment-Resistant Depression NCT03134066	Massachusetts General Hospital	—
Completed	Structural and Functional Connectivity of Brainstem Monoamine Pathways in Treatment Resistant Depression NCT03109717	Kathryn O'Connor	—
Unknown	D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression NCT02772211	Sheba Medical Center	Phase 4
Terminated	Long Term Follow-up of Deep Brain Stimulation for Treatment-Resistant Depression NCT03360942	Dartmouth-Hitchcock Medical Center	N/A
Completed	Treatment Resistant Depression and Insomnia in Older Veterans NCT02971150	VA Pittsburgh Healthcare System	N/A
Completed	Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers, and M NCT02611206	University of Minnesota	N/A
Completed	A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression NCT02497287	Janssen Research & Development, LLC	Phase 3
Completed	A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Ora NCT02417064	Janssen Research & Development, LLC	Phase 3
Completed	A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an NCT02418585	Janssen Research & Development, LLC	Phase 3
Completed	Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depre NCT02522377	The Cleveland Clinic	N/A
Completed	Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression NCT02360280	VA Office of Research and Development	Phase 2
Completed	Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) NCT01920555	Massachusetts General Hospital	Phase 2
Completed	Implementation Trial of Evidence Based Practices for Mood Disorders NCT02150577	University of Arkansas	N/A
Active Not Recruiting	Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression NCT02046330	The University of Texas Health Science Center, Houston	N/A
Terminated	Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression NCT01913535	Massachusetts General Hospital	Phase 2
Unknown	Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population NCT01868802	Paul J. Lamothe	Phase 2
Active Not Recruiting	Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S NCT01984710	Emory University	N/A
Unknown	Focal Electrically Administered Seizure Therapy for the Treatment of Depression NCT02462551	Ziad Nahas	N/A
Completed	Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy NCT01935115	University of Saskatchewan	Phase 4
Completed	Low Field Magnetic Stimulation for Treatment Resistant Depression NCT01944644	Weill Medical College of Cornell University	N/A
Completed	Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD) NCT01898429	Paul Holtzheimer	N/A
Completed	Action of Ketamine in Treatment-Resistant Depression NCT01945047	University of Ottawa	Phase 2 / Phase 3
Unknown	Interpersonal Psychotherapy for Treatment Resistant Depression NCT01896349	Hospital de Clinicas de Porto Alegre	N/A
Completed	An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay NCT01507155	Genomind, LLC	N/A
Completed	Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depressi NCT01654796	Massachusetts General Hospital	N/A
Completed	Coupling Repetitive Transcranial Magnetic Stimulation With a Neuronavigation System in Treatment Resistant Dep NCT01677078	Rennes University Hospital	N/A
Terminated	A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression NCT01687478	Eli Lilly and Company	Phase 3
Terminated	Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder NCT01598324	Mclean Hospital	—
Terminated	Pharmacogenomics for Antidepressant Guidance and Education NCT01555021	Massachusetts General Hospital	—
Completed	Exercise in Treatment Resistant Depression (TRD): A Feasibility Study NCT01383811	Milton S. Hershey Medical Center	N/A
Unknown	A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression NCT01801319	Abbott Medical Devices	N/A
Completed	Pulsating ElectroMagnetive Treatment (PEMF) at Treatment Resistant Depression NCT01353092	Hillerod Hospital, Denmark	Phase 3
Completed	Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression NCT01246908	CeNeRx BioPharma Inc.	Phase 2
Completed	A Study in Relapse Prevention of Treatment-Resistant Depression NCT00958568	Eli Lilly and Company	Phase 3
Completed	A Pilot Study of the Use of Magnetic Seizure Therapy for Depression NCT00808938	Bayside Health	Phase 2
Completed	Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients NCT00789854	AstraZeneca	Phase 3
Withdrawn	Ketamine Frequency Treatment for Major Depressive Disorder NCT00646087	Essentia Health	Phase 4
Active Not Recruiting	Epidural Cortical Stimulation for Depression NCT00565617	Medical University of South Carolina	N/A
Completed	Berlin Deep Brain Stimulation Depression Study NCT00531726	Charite University, Berlin, Germany	N/A
Unknown	Deep Brain Stimulation in Treatment Resistant Depression NCT01435148	North Bristol NHS Trust	N/A
Withdrawn	Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment NCT00178854	Vanderbilt University Medical Center	Phase 4